Safety of intranasal palivizumab in healthy adult volunteers
- Conditions
- RSV
- Registration Number
- NL-OMON23479
- Lead Sponsor
- ouis Bontl.bont@umcutrecht.nl
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Adult men and women between the ages of 18 and 50 in good health based on relevant medical history
Exclusion Criteria
Adults with nasal cold or obstructions in the nasal cavity; history of respiratory symptoms or serious infectious disease within 4 weeks prior to drug administration; immunocomprimised; nasal surgery prior to or during trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Self-reported according to FDA scorecard and SAEs.
- Secondary Outcome Measures
Name Time Method Symptoms observed 10 minutes after first adminstration; viral diagnostics